Trials / Terminated
TerminatedNCT05577715
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb-202 | Specified dose on specified days |
Timeline
- Start date
- 2022-11-14
- Primary completion
- 2024-08-12
- Completion
- 2024-08-12
- First posted
- 2022-10-13
- Last updated
- 2025-09-04
- Results posted
- 2025-09-04
Locations
33 sites across 6 countries: United States, Australia, Belgium, Chile, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05577715. Inclusion in this directory is not an endorsement.